https://ag-881inhibitor.com/in....creased-output-of-po
COMBI-AD revealed adjuvant dabrafenib and trametinib increasing RFS compared with placebo (HR 0.49; 95% CI 0.40-0.59). Checkmate-238 demonstrated an improvement in RFS of adjuvant nivolumab over ipilimumab (HR 0.68, P less then 0.001) whilst Keynote-054 demonstrated a noticable difference in RFS with adjuvant pembrolizumab over placebo (HR 0.57, P less then 0.001). Numerous nuances should be considered when interpr
Like
Comment
Share
